Anti-TNFRSF12A / TWEAKR / CD266 Reference Antibody (enavatuzumab)
Recombinant Antibody
- 产品详情
- 实验流程
Application ![]()
| FC, Kinetics, Animal Model |
---|---|
Primary Accession | Q9NP84 |
Reactivity | Human |
Clonality | Monoclonal |
Isotype | IgG1 |
Calculated MW | 13911 Da |
Target/Specificity | TNFRSF12A / TWEAKR / CD266 |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | TNFRSF12A |
---|---|
Synonyms | FN14 |
Function | Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins. |
Cellular Location | Membrane; Single-pass type I membrane protein. |
Tissue Location | Highly expressed in heart, placenta and kidney. Intermediate expression in lung, skeletal muscle and pancreas |
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,500.00
Cat# APR10399